Abcam (NASDAQ:ABCM) versus Brookline Capital Acquisition (NASDAQ:BCAC) Head-To-Head Analysis

Abcam (NASDAQ:ABCM – Get Rating) and Brookline Capital Acquisition (NASDAQ:BCAC – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Valuation and Earnings

This table compares Abcam and Brookline Capital Acquisition’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	$401.06 million	7.97	$5.92 million	N/A	N/A
Brookline Capital Acquisition	N/A	N/A	-$480,000.00	N/A	N/A

Abcam has higher revenue and earnings than Brookline Capital Acquisition.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Abcam and Brookline Capital Acquisition, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abcam	0	1	1	0	2.50
Brookline Capital Acquisition	0	0	0	0	N/A

Institutional & Insider Ownership

13.9% of Abcam shares are held by institutional investors. Comparatively, 51.8% of Brookline Capital Acquisition shares are held by institutional investors. 6.7% of Abcam shares are held by company insiders. Comparatively, 19.2% of Brookline Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Abcam and Brookline Capital Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
Brookline Capital Acquisition	N/A	-416.32%	-4.75%

Risk & Volatility

Abcam has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Brookline Capital Acquisition has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.

Summary

Abcam beats Brookline Capital Acquisition on 6 of the 8 factors compared between the two stocks.

About Abcam

(Get Rating)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

About Brookline Capital Acquisition

(Get Rating)

Brookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.